Video

What recent pembrolizumab/enfortumab vedotin data mean for treatment of metastatic urothelial cancer

Author(s):

Urology Times staff
Conference|ESMO Annual Congress

“These data do suggest that [enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda)] is a viable treatment option for cisplatin-ineligible patients,” says Jonathan E. Rosenberg, MD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Jonathan E. Rosenberg, MD, discusses the implications of the findings of the ESMO Congress 2022 abstract, “Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC).” Rosenberg is chief of the Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology, and Enno W. Ercklentz Chair at Memorial Sloan Kettering Cancer Center in New York, New York.

      Related Videos
      Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
      Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
      Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
      Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
      Laura Bukavina, MD, highlights study of urinary microbiome profiling
      Laura Bukavina, MD, highlights study of urinary microbiome profiling
      Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
      Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
      Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
      Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
      ASCO GU recap: Insights on 5 key trials
      ASCO GU recap: Insights on 5 key trials
      Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
      Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
      Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
      Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
      Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
      Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
      David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
      David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
      Related Content
      CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC
      February 20th 2025

      CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

      Thomas E. Hutson, DO, PharmD
      "The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
      Former MLB player Dave Winfield shares lessons from baseball, philanthropy
      November 15th 2024

      Former MLB player Dave Winfield shares lessons from baseball, philanthropy

      Urology Times staff
      In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
      Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC
      February 18th 2025

      Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC

      Hannah Clarke
      However, the triplet regimen did not lead to an improvement in overall survival.
      blurred photo of a clinic hallway
      May 28th 2023

      2023 AUA highlights in benign urology

      Urology Times staff
      Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
      Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
      February 16th 2025

      Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

      Benjamin P. Saylor
      "The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
      Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
      February 15th 2025

      Latest LITESPARK-003 data highlight antitumor activity of belzutifan plus cabozantinib

      Benjamin P. Saylor
      ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2.
      © 2025 MJH Life Sciences

      All rights reserved.